

MedGenome secures \$30 million

BUSINESS BUREAU

Hyderabad

MedGenome, Bengaluru-based genomics research and diagnostics company, announced completion of \$30 million in Series C financing led by Sequoia India and Sofina, with participation by Zodius Capital; Kris Gopalakrishnan, co-founder and former CEO of Infosys; and Lakshmi Narayanan, former CEO of Cognizant.

The Series C funding will accelerate development of the company's diagnostics tests and expand the market penetration by increasing customer awareness on the importance of genetic tests. Additionally, the funding will also be used to broaden

biomarker discovery programmes.

MedGenome operates the largest Next Generation Sequencing (NGS) lab in South East Asia, and a CLIA-certified, CAP-accredited sequencing lab in Foster City, CA. The company's services are being leveraged by pharmaceutical and biotech companies across the globe. MedGenome's diagnostics tests include many firsts for genetic diagnostics in India, including first liquid biopsy "OncoTrack" for monitoring cancer treatment, non-invasive prenatal screening test (NIPT) for pregnant women, carrier screening test for couples planning on a baby, and whole exome sequencing test for identifying muta-



SERIES C FUNDING: Sequoia India and Sofina backed funding to help the company to accelerate diagnostics development.

tions in rare diseases.

With over a million babies born each year with genetic disorders, India carries a huge genetic disorder burden.

"Precision medicine is the

ultimate goal of clinicians and patients alike which can be enabled through extensive biomarker discovery," said Sam Santhosh, founder and chairman of MedGenome.